These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31258629)

  • 1. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
    Wesolowski R; Sharma N; Reebel L; Rodal MB; Peck A; West BL; Marimuthu A; Severson P; Karlin DA; Dowlati A; Le MH; Coussens LM; Rugo HS
    Ther Adv Med Oncol; 2019; 11():1758835919854238. PubMed ID: 31258629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
    Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
    Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
    Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
    Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
    Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.
    Boal LH; Glod J; Spencer M; Kasai M; Derdak J; Dombi E; Ahlman M; Beury DW; Merchant MS; Persenaire C; Liewehr DJ; Steinberg SM; Widemann BC; Kaplan RN
    Clin Cancer Res; 2020 Dec; 26(23):6112-6121. PubMed ID: 32943455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors.
    Manji GA; Van Tine BA; Lee SM; Raufi AG; Pellicciotta I; Hirbe AC; Pradhan J; Chen A; Rabadan R; Schwartz GK
    Clin Cancer Res; 2021 Oct; 27(20):5519-5527. PubMed ID: 34321280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer.
    Yu M; Wu Y; Li Q; Hong W; Yang Y; Hu X; Yang Y; Lu T; Zhao X; Wei X
    Genes Dis; 2024 May; 11(3):100989. PubMed ID: 38303927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
    Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
    Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
    Omstead AN; Paskewicz M; Gorbunova A; Zheng P; Salvitti MS; Mansoor R; Reed P; Ballengee S; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
    Carcinogenesis; 2022 Oct; 43(9):842-850. PubMed ID: 35552655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
    Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
    Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
    Rosenbaum E; Kelly C; D'Angelo SP; Dickson MA; Gounder M; Keohan ML; Movva S; Condy M; Adamson T; Mcfadyen CR; Antonescu CR; Hwang S; Singer S; Qin LX; Tap WD; Chi P
    Oncologist; 2019 Oct; 24(10):1309-e983. PubMed ID: 31213500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
    Stathis A; Hess D; von Moos R; Homicsko K; Griguolo G; Joerger M; Mark M; Ackermann CJ; Allegrini S; Catapano CV; Xyrafas A; Enoiu M; Berardi S; Gargiulo P; Sessa C;
    Invest New Drugs; 2017 Dec; 35(6):766-772. PubMed ID: 28317088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
    Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
    Johnson ML; Wang JS; Falchook G; Greenlees C; Jones S; Strickland D; Fabbri G; Kennedy C; Elizabeth Pease J; Sainsbury L; MacDonald A; Schalkwijk S; Szekeres P; Cosaert J; Burris H
    Br J Cancer; 2023 May; 128(10):1906-1915. PubMed ID: 36871042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.
    Bauer TM; Patel MR; Forero-Torres A; George TJ; Assad A; Du Y; Hurwitz H
    Onco Targets Ther; 2018; 11():2399-2407. PubMed ID: 29750040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.